107 related articles for article (PubMed ID: 2561162)
1. Cardiovascular responses to a newly developed phosphodiesterase inhibitor, DN-9693 [7-pyperidinyl-1,2,3,5-tetrahydroimidazo (2,1-b)-quinazolin-2-one.HCl] in dog cross-circulated atrial and ventricular preparations.
Akahane K; Furukawa Y; Haniuda M; Karasawa Y; Chiba S
Jpn Heart J; 1989 Nov; 30(6):903-15. PubMed ID: 2561162
[TBL] [Abstract][Full Text] [Related]
2. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
Alvarez R; Banerjee GL; Bruno JJ; Jones GL; Littschwager K; Strosberg AM; Venuti MC
Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320
[TBL] [Abstract][Full Text] [Related]
3. Increase in calcium sensitivity of cardiac myofibrils contributes to the cardiotonic action of sulmazole.
van Meel JC; Zimmermann R; Diederen W; Erdman E; Mrwa U
Biochem Pharmacol; 1988 Jan; 37(2):213-20. PubMed ID: 2829914
[TBL] [Abstract][Full Text] [Related]
4. Positive chronotropic and inotropic effects of pimobendan (UD-CG 115 BS) in isolated, cross-circulated canine heart preparations.
Furukawa Y; Akahane K; Ogiwara Y; Haniuda M; Chiba S
Arch Int Pharmacodyn Ther; 1989; 300():159-73. PubMed ID: 2575887
[TBL] [Abstract][Full Text] [Related]
5. Effects of DN-9693, a synthesized phosphodiesterase inhibitor, on pancreatic exocrine secretion in dogs.
Iwatsuki K; Horiuchi A; Yonekura H; Haruta K; Homma N; Chiba S
Jpn J Pharmacol; 1989 Jan; 49(1):77-82. PubMed ID: 2470943
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular responses to a newly developed cardiotonic agent, ZSY-39 [4-methyl-5-(4-pyridinyl)-thiazole-2-carboxyamide] in dog cross-circulated atrial and ventricular preparations.
Chiba S; Furukawa Y; Saegusa K; Ogiwara Y; Takeda M
Jpn Heart J; 1987 Mar; 28(2):253-60. PubMed ID: 3599412
[TBL] [Abstract][Full Text] [Related]
7. Positive inotropic and negative chronotropic effects of OPC-8490, a newly developed cardiotonic, in isolated, blood-perfused canine heart preparations.
Furukawa Y; Akahane K; Haniuda M; Chiba S
Jpn Heart J; 1989 May; 30(3):387-98. PubMed ID: 2552190
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological analysis of positive chrono- and inotropic responses to denopamine (TA-064) in dog cross-circulated atrial and ventricular preparations.
Akahane K; Furukawa Y; Karasawa Y; Ren LM; Chiba S
Jpn J Pharmacol; 1990 Jan; 52(1):69-79. PubMed ID: 1968521
[TBL] [Abstract][Full Text] [Related]
9. Comparison of vasodilator effects of DN-9693, a selective inhibitor of cyclic AMP phosphodiesterase, and isobutylmethylxanthine, a non-selective one, in dogs.
Hashimoto H; Ishii K; Satoh K; Taira N
Jpn J Pharmacol; 1987 Aug; 44(4):405-12. PubMed ID: 2446035
[TBL] [Abstract][Full Text] [Related]
10. Bradycardic effect of alinidine on in situ and on isolated, blood-perfused heart preparations of dogs.
Ogiwara Y; Furukawa Y; Saegusa K; Takeda M; Chiba S
Arch Int Pharmacodyn Ther; 1988; 291():41-54. PubMed ID: 2835022
[TBL] [Abstract][Full Text] [Related]
11. Effects of DN-9693, a selective inhibitor of cyclic AMP phosphodiesterase, in isolated and perfused canine large coronary arteries.
Nakane T; Chiba S
Jpn J Pharmacol; 1988 Dec; 48(4):507-9. PubMed ID: 2468805
[TBL] [Abstract][Full Text] [Related]
12. Inotropic and chronotropic activity of a new cardiotonic agent, DM 9278 (1,2,3,4,8,9,10,12-octahydro[2,1-b]pyrido[2,3-f]quinazolin-9-one ), on isolated dog atrial and ventricular muscles.
Chiba S; Furukawa Y; Saegusa K; Ogiwara Y
Jpn Heart J; 1986 May; 27(3):387-94. PubMed ID: 3761569
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular effects of ZSY-27 [5-methyl-6-(4-pyridinyl)-2H-1,4-thiazine-3(4H)-one X hydrochloride] in the dog cross-circulated atrial preparation.
Chiba S; Furukawa Y; Saegusa K; Ogiwara Y
Jpn Heart J; 1986 Sep; 27(5):749-57. PubMed ID: 3820580
[TBL] [Abstract][Full Text] [Related]
14. Species-dependent pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 58993 and WIN 62005.
Dundore RL; Pagani ED; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
J Cardiovasc Pharmacol; 1995 Jan; 25(1):14-21. PubMed ID: 7723343
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the cardiovascular and biochemical profiles of a new positive inotropic drug, AR-L 115 BS, with those of theophylline.
Morita T; Satoh K; Taira N
Jpn Heart J; 1984 May; 25(3):447-60. PubMed ID: 6088829
[TBL] [Abstract][Full Text] [Related]
16. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.
von der Leyen H; Mende U; Meyer W; Neumann J; Nose M; Schmitz W; Scholz H; Starbatty J; Stein B; Wenzlaff H
Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):90-100. PubMed ID: 1723153
[TBL] [Abstract][Full Text] [Related]
17. DN 9693: a phosphodiesterase inhibitor with a platelet membrane effect.
Jackson C; Ball J; Peel J; Lawry J; Greaves M; Preston FE
Thromb Haemost; 1989 Apr; 61(2):266-9. PubMed ID: 2546286
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of the cardiovascular and biochemical actions of the imidazo [4,5b] pyridine sulmazole and an imidazo [4,5c] pyridine analogue, BW A746C.
Allan G; Cambridge D; Follenfant MJ; Stone D; Whiting MV
Br J Pharmacol; 1988 Feb; 93(2):387-98. PubMed ID: 3359112
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular effects of a new phenoxyalkylamine derivative, 2-isopropyl-5-[3-(2-methoxyphenoxy)propylamino]-2-(3,4,5-trimethoxy phenyl) valeronitrile fumarate (HV-525), in cross-circulated dog atrial preparations.
Chiba S; Ogiwara Y; Furukawa Y; Saegusa K
Jpn Heart J; 1987 Mar; 28(2):261-72. PubMed ID: 3599413
[TBL] [Abstract][Full Text] [Related]
20. Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes.
Kelso EJ; McDermott BJ; Silke B
Br J Pharmacol; 1993 Dec; 110(4):1387-94. PubMed ID: 8306078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
